While the last decade has brought considerable progress for patients with DMD, substantial unmet need remains. Several ...
In year two of the trial, Elevidys demonstrated statistically significant and clinically improvements across three key ...
H.C. Wainwright adjusted its financial outlook for PepGen Inc. (NASDAQ:PEPG), reducing the price target to $16.00 from the ...
Riding recent momentum in the Duchenne muscular dystrophy space, Capricor Therapeutics, Wave Life Sciences, Regenxbio and ...
Roche and Sarepta Therapeutics have shared positive top-line results from a late-stage study of Elevidys (delandistrogene ...
KOIN Portland on MSN1d
Vancouver family launches son’s ashes into spaceA Vancouver family is sending their son on one final journey into the stars, where his ashes will eventually transform into a ...
Muscular dystrophy is caused by defects in certain genes, with type determined by the abnormal gene. In 1986, researchers discovered the gene that, when defective or flawed, causes Duchenne ...
The gene therapy delandistrogene moxeparvovec-rokl showed clinically meaningful benefits and disease stabilization at 2 years ...
Excellence Awards have once again brought together top candidates and outstanding schools, in a celebration of academic ...
PepGen (PEPG) “provided recent updates on its CONNECT clinical program investigating PGN-EDO51 in Duchenne muscular dystrophy for patients ...
(RTTNews) - Sarepta Therapeutics, Inc. (SRPT) Monday reported positive topline results from Part 2 of the Phase 3 study, dubbed EMBARK, of its gene therapy Elevidys approved for the treatment of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback